references/trial_operations.md
Trial Operations and Feasibility
Reference for study feasibility and the phase-gate decision. Pairs with phase_gate_scorer.py.
Feasibility is the silent killer
Most trials that fail do not fail on science — they fail on enrollment. A study powered for 240 patients across 18 sites assumes a recruitment rate per site per month that is often optimistic by 2-3×. The feasibility scorer enforces two reality checks: the eligible pool ratio (eligible population ÷ target enrollment should comfortably exceed 3×, ideally 10×) and site capacity (sites × nominal enroll rate × duration vs target). The "enrolling funnel" loses patients at screening, eligibility, and consent — Lasagna's Law (clinicians overestimate the eligible pool the moment a trial opens) is the operative caution.
Good Clinical Practice (GCP)
ICH E6(R2) — and the in-progress E6(R3) — define the responsibilities of sponsors, investigators, and monitors; informed consent; protocol adherence; and the trial master file. A study design that cannot satisfy GCP roles is not gate-ready. Name the Principal Investigator, Medical Monitor, and Biostatistician before the gate.
Risk-based monitoring (RBM)
Centralized, risk-based monitoring (FDA's 2013 guidance, expanded 2023; TransCelerate's RBM methodology) replaces 100% source-data verification with targeted monitoring of the data and processes that most affect patient safety and data integrity. Building RBM into the design lowers operational complexity (a scored dimension).
Operational complexity drivers
Visits per patient, invasive procedures, central-lab logistics, imaging adjudication, and the number of countries all raise operational complexity and recruitment difficulty. The scorer inverts complexity (simpler design → higher score) because every added visit or procedure raises dropout and cost-per-patient.
Budget reality
Cost-per-patient varies enormously by area (a digital-therapeutic at ~$6k/patient vs a biologic at ~$50k+/patient). The scorer compares planned budget to a profile benchmark and flags under-funding below 75% of benchmark. Research-finance (the sibling skill) owns the full program budget; this scorer only checks gate-level adequacy.
Sources
- ICH E6(R2), Good Clinical Practice (2016); ICH E6(R3) draft (2023).
- FDA, A Risk-Based Approach to Monitoring of Clinical Investigations (2013; Q&A revision 2023).
- TransCelerate BioPharma, Risk-Based Monitoring Methodology position papers.
- CTTI (Clinical Trials Transformation Initiative), Recruitment and Feasibility recommendations.
- Lasagna, L. — "Lasagna's Law" on the overestimation of eligible patients (clinical-trials folklore widely cited in feasibility literature).
- Treweek et al., Strategies to improve recruitment to randomised trials — Cochrane Database Syst Rev 2018.
- Getz & Campo, Trial complexity and protocol design — Tufts CSDD impact reports.